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ABSTRACT 
Protein arginine methyltransferase 5 (PRMT5) has emerged as a key regulator of tumorigenesis. However, how 
PRMT5 functions in bladder cancer, the most common malignancy of the urological system, is unknown. We 
described here that PRMT5 is highly expressed in bladder cancer cell lines and primary human bladder cancer 
tissues. PRMT5 enhances the proliferation and colony formation of bladder cancer cells. PRMT5 knockdown 
induces bladder cancer cell apoptosis. Mechanistically, PRMT5 enhances NF-kB activation by targeting crucial 
anti-apoptotic genes such as BCLXL and c-IAP1, thereby inhibiting tumor cell apoptosis and sustaining prolifera-
tion. Importantly, PRMT5 inhibitor opposed tumor growth and BCLXL and c-IAP1 transcription in the bladder 
cancer xenograft model. Collectively, the current suggests the crucial role of PRMT5 as a promising therapeutic 
target in bladder cancers. 
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INTRODUCTION  
Bladder cancer is the most common uro-
logical carcinoma with about 430 000 cases 
and 165 000 deaths worldwide each year 
(Antoni et al., 2017). Transitional cell carci-
noma is the most common histological type of 
bladder cancer, accounting for more than 
90 % of all cases (Torre et al., 2015) . Radical 
cystectomy combined with chemotherapy is 
the major therapeutic strategy for bladder can-
cer patients, but the overall 10-year survival 
after radical cystectomy remains grave (Shen 
et al., 2009; Witjes et al., 2014). Therefore, 
the mechanism behind the progression and tu-
morigenesis of bladder cancer urgently re-
quires investigation for development of novel 
therapeutic agents.  
RMT5 is a member of the protein arginine 
methyltransferase (PRMT) family and cata-
lyzes arginine methylation by transferring 
methyl groups to arginine residues (Bedford 
and Clarke, 2009; Blanc and Richard, 2017). 
The modifications catalyzed by PRMT5 take 
an important role in lots of cellular processes 
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(Karkhanis et al., 2011; Yang and Bedford, 
2013). Extensive studies have shown that 
PRMT5 is overexpressed in varieties of hu-
man lymphoid malignancies and solid tumors, 
and it facilitates survival and proliferation of 
cancer cells (Chan-Penebre et al., 2015; 
Harris et al., 2014; Karkhanis et al., 2011). 
PRMT5 induces arginine methylation of tu-
mor suppressor p53 on the arginine 333,335 
and 337 and affects the p53 target gene spec-
ificity, thereby escaping p53 surveillance and 
leading to tumorigenesis (Jansson et al., 2008; 
Li et al., 2015). PRMT5 potently activates 
NF-кB by dimethylation of its p65 subunit on 
arginine 30 (Wei et al., 2013). It’s well recog-
nized that PRMT5 contributes to malignant 
processing, however, its role in bladder can-
cer is never reported. 
In the present study, we showed for the 
first time a potential role of PRMT5 in pro-
moting bladder cancer cell proliferation and 
tumor growth in vitro and in vivo. Mechanis-
tically, PRMT5 promotes NF-κB recruitment 
on the promoter of anti-apoptotic targets 
BCLXL and c-IAP1. Our work thus demon-
strated PRMT5 is crucial for facilitating blad-
der cancer growth, and is an important target 
for cancer therapy.  
 
MATERIALS AND METHODS 
Cell culture, plasmids and lentivirus 
T24 and UM-UC-3 were from ATCC and 
were maintained in RPMI 1640 (Invitrogen) 
with 10 % fetal bovine serum (Invitrogen), 
100 U/ml penicillin, and 100 U/ml streptomy-
cin, in 5 % CO2 at 37 °C. The primary human 
bladder cancer tissues were obtained from pa-
tients with invasive transitional carcinoma. 
293T cells were transient transfected with hu-
man PRMT5 shRNA (Dharmacon) with 
Lipofectamine and plus reagent (Invitrogen) 
to produce lentiviral supernatant. T24 and 
UM-UC-3 cells were infected with shPRMT5 
lentivirus to stably overexpress PRMT5 
shRNA. 
 
Western blot analysis 
Western blot was carried out as previously 
described (Li et al., 2010). Antibodies used 
were: PRMT5 (PRMT5-21, Santa Cruz), 
cleaved caspase-3 (5A1E, CST) and GAPDH 
(14C10, Cell Signaling Technology). 
 
Cell proliferation and colony formation  
assay 
1 × 106 cells were seeded in 10 cm dishes 
in RPMI 1640 containing 10 % FBS. Cell 
numbers were counted in 2 and 4 days. For 
colony formation assay, 50/well cells were 
placed in six-well plates in RPMI 1640 con-
taining 10 % FBS for 10 days. Colonies were 
fixed with methanol and stained with 0.1 % 
crystal violet in 20 % methanol for 15 min. 
 
Annexin V apoptosis assay  
The cells were stained with PE-annexin 
V/7-AAD according to the manufacturer's in-
struction (BD Biosciences). 
 
Small interfering RNA (siRNA)  
siGENOME SMART pool targeting 
PRMT5 or control random siRNA were from 
Dharmacon. T24 cells were transfected with 
50 nM siPRMT5 by Lipofectamine RNAi 
MAX reagent (Invitrogen). 
 
Luciferase assay  
p5XIP10 [21] was transfected in T24 cells 
using Lipofectamine and Plus Reagents (Invi-
trogen). 48 hours later, the NF-кB luciferase 
activity was monitored (Reporter Lysis 
Buffer kit, Promega). 
 
Quantitative PCR  
Total RNA was extracted using the RN- 
easy FFPE Kit (Qiagen) or RNeasy Mini kit 
(Qiagen). cDNA was prepared by the Super-
Script III First-Strand Synthesis Kit (Invitro-
gen). qPCR was performed using SYBR 
Green Master Mix (Appliedbiosystems). Pri-
mers were designed by Primer3 (v.0.4.0)  
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Chromatin immunoprecipitation (ChIP)  
The truChIP Chromatin Shearing Kit (Co-
varis) was used to prepare chromatin. Chro-
matin was sheared into 200- to 700-bp frag-
ments using a Covaris S2 instrument (duty cy-
cle, 2 %; intensity, 3; 200 cycles per burst; 4 
min). The IgG and NF-kB p65 antibodies 
(2A12A7, Thermo Fisher) were used for im-
munoprecipitation by the Quick Chip Kit 
(Imgenex SYBR Green Master Mix, (Ap-
pliedbiosystems) was used for qPCR to quan-
tify precipitated DNA). The primers are from 
Qiagen EpiTect ChIP qPCR primers. 
 
Xenograft study 
1 × 106 T24 cells were injected subcuta-
neously into C57BL/6J mice (Shanghai La-
boratory Animal Center) in the right flank. 
Tumor volume was measured using calipers 
and calculated as follows: volume = longest 
tumor diameter × (shortest tumor diame-
ter)2/2. EPZ015666 or control vehicle (PBS) 
was administered orally twice daily (50 
mg/kg) from 14 days after injection. Mice 
were sacrificed 28 days after injection.  
 
Statistical analysis 
Data were analyzed using GraphPad 
Prism 7. The statistical difference was calcu-
lated by using two-tailed Student t test or one-
way ANOVA. A P-value below 0.05 was 
considered significant. 
 
RESULTS 
PRMT5 is overexpressed in bladder cancer 
To examine if PRMT5 is a tumor pro-
moter in bladder cancer, we first tested 
PRMT5 protein expression in bladder cancer 
cell lines. As illustrated in Figure 1A, com-
pared to human normal bladder cell lines 
HBSMC and SV-HUC-1, PRMT5 protein 
levels were much higher in human bladder 
cancer cells (T24 and UM-UC-3). The pri-
mary human bladder cancer tissues were fur-
ther used to detect PRMT5 protein levels. We 
showed that PRMT5 levels were notably 
higher in both primary bladder cancers, as 
compared to the normal adjacent tissue (Fig-
ure 1B). Furthermore, PRMT5 transcription 
was also up-regulated in bladder cancer FFPE 
samples, as compared to samples from 
healthy control (Figure 1C). These data indi-
cated that PRMT5 is substantially overex-
pressed in bladder cancer. 
 
Figure 1: Expression level of PRMT5 is higher 
in bladder cancer cell lines and primary tis-
sues. A. Western blot of PRMT5 protein in blad-
der cancer cells (T24 and UM-UC-3) and control 
normal bladder cell lines (HBSMC and SV-HUC-
1). B. PRMT5 expression level in primary bladder 
cancer tissues (primary cancer 1 and primary can-
cer 2) and control normal bladder cancer adjacent 
tissue (normal). C. The relative expression of 
PRMT5 in 10 pairs of FFPE samples from bladder 
cancer patients and healthy controls was ana-
lyzed by qRT-PCR. ** P < 0.01 vs. healthy control. 
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PRMT5 facilitates bladder cancer cell 
growth 
PRMT5 is highly expressed in bladder 
cancer. Next, we knockdown the endogenous 
PRMT5 protein to investigate its role on blad-
der cancer growth. We detected the effect of 
PRMT5 knockdown on cell proliferation and 
colony formation of T24 and UM-UC-3 cells. 
shPRMT5 lentivirus were transduced into 
T24 and UM-UC-3 cells to establish stable 
cells overexpressing PRMT5 shRNA. West-
ern blot confirmed the striking knockdown ef-
ficiency of shPRMT5 (Figure 2A). We further 
demonstrated that knockdown of PRMT5 in 
T24 and UM-UC-3 cells with shRNA resulted 
in much slower growth curve (Figure 2B), 
strongly suggesting that PRMT5 is the pro-
moter for cell proliferation. Furthermore, 
shPRMT5 knockdown led to a dramatic de-
crease in the colony number in T24 and UM-
UC-3 cells (Figure 2C), supporting the onco-
genicity of PRMT5. Re-expression of 
PRMT5 in the shPRMT5 cells re-increased 
the potential of proliferation and colony for-
mation in bladder cancer cells, further con-
firming the crucial role of PRMT5 in the neo-
plastic growth of bladder cancer (Figure 2A, 
2B and 2C). These data collectively provide 
strong evidence for the tumor promoting po-
tential of PRMT5 in human bladder cancer. 
 
PRMT5 knockdown leads to apoptosis of 
bladder cancer cells 
We next detected if apoptosis contributes 
to decreased cell proliferation in PRMT5 
knockdown bladder cancer cells. Flow cytom-
etry showed the proportions of apoptotic cells 
by Annexin V/7-AAD staining (Figure 3A). 
48 h after siPRMT5 transaction, the percent-
age of apoptotic cells was substantially en-
hanced compared with the sicontrol treated 
cells (Figure 3B). We further proved the cell 
apoptosis by Western blot, which showed in-
creased protein levels of cleaved-caspase-3 in 
response to PRMT5 siRNA (#1 and #2). 
These results demonstrated that PRMT5 
knockdown resulted in apoptosis in bladder 
cancer cells. 
 
PRMT5 inbibition suppresses NF-κB  
activativity and its target gene expression 
PRMT5 induces NF-κB activation by di-
methylating R30 of the p65 subunit (Wei et 
al., 2013). In Figure 4A, we showed that 
PRMT5 inhibition by shRNA knockdown led 
to significant NF-κB inactivation. We used 
PRMT5 inhibitor, EPZ015666, to further de-
termine its role on NF-κB activity. As indi-
cated in Figure 4B, 100 and 200 µM of 
EPZ015666 caused supression in NF-κB ac-
tivity in T24 cells. The NF-κB transcription 
family is crucial for multiple gene transcrip-
tion in cell growth, apoptosis and neoplastic 
transformation. To identify the relevant target 
genes that are controlled by the PRMT5–NF-
κB activation axis, we detected some of the 
NF-κB candidate genes by qRT–PCR. Our 
data suggested that c-IAP1 and BCLXL were 
strikingly suppressed in the shPRM5 knock-
down T24 cells (Figure 4C & 4D, left panels). 
Similarly, PRMT5 inhibitor EPZ015666 sig-
nificantly inhibited NF-κB activation and its 
target gene trasncription in T24 bladder can-
cer cells (Figure 4C & 4D, right panels). 
Overall, these results support a model in 
which NF-kB-dependent anti-apoptotic genes 
c-IAP1 and BCLXL are crucial for PRMT5-
mediated tumor growth in human bladder 
cancer. 
Chromatin immunoprecipitation (ChIP) 
was performed using T24 bladder cancer cells 
treated with EPZ015666 to address critical 
roles of PRMT5 on NF-кB recruitment. Phar-
macological inhibition of PRMT5 by 
EPZ015666 significantly impairs NF-κB p65 
occupancy on c-IAP1 and BCLXL promoters, 
(Figure 4E), providing further molecular in-
sights into PRMT5 function.  
 
Pharmacological inhibition of PRMT5  
regulates apoptosis and impedes tumor 
growth in vivo 
To confirm the essential role of PRMT5 
as a therapeutic target in vitro, we investi-
gated the effect of EPZ015666, a selective 
PRMT5 inhibitor (Braun et al., 2017; Chan-
Penebre et al., 2015), on bladder tumor growth.
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Figure 2: PRMT5 promotes bladder cancer cell proliferation. A. shPRMT5 knockdown and overex-
pression of PRMT5 in T24 (left) and UM-UC-3 (right) cells. B. Cell numbers in the shPRMT5 knockdown 
and overexpression of PRMT5 cells. C. The influence of PRMT5 knockdown on the cell survival of T24 
(left) and UM-UC-3 (right) cells are measured by the clonogenic survival assay. * P < 0.05, ** P < 0.01. 
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Figure 3: PRMT5 knockdown increases apoptosis in bladder cancer cells. T24 cells were trans-
fected with siPRMT5 (#1or #2) or control siRNA (siControl) for 48 h. A. Annexin V/7-AAD staining of 
T24 cells. B. Statistics of Figure A. ** P < 0.01 vs. control. C. Western blots for PRMT5 and caspase-3 
protein expression.  
 
 
Administration of EPZ015666 did not lead to 
any body weight loss in tumor-bearing mice 
(Figure 5B). However, a 14-day EPZ015666 
treatment resulted in significant reduction in 
tumor volume (Figures 5A and 5C). Moreo-
ver, EPZ015666 caused remarkable decrease 
of BCLXL and c-IAP1 transcription (Figure 
5D), confirming our in vitro findings con-
cerning the associations between NF-кB ac-
tivation, BCLXL/c-IAP1 downregulation and 
apoptosis induced by genetic and pharmaco-
logical and genetic inhibition of PRMT5. We 
therefore propose that PRMT5 is a promising 
drug target in bladder cancer. 
 
DISCUSSION 
Protein arginine methyltransferase 5 
(PRMT5) is a member of the PRMT family of 
proteins, which symmetrically is dimethylat-
ing histones and non-histone protein. It’s 
highlighted that PRMT5 plays central roles in 
the regulation of diverse cellular signaling 
and gene expression. PRMT5 protein levels 
are frequently high in numerous human can-
cers, such as lymphoma, glioblastoma, esoph-
ageal cancer, lung cancer, etc (Braun et al., 
2017; Chan-Penebre et al., 2015; Jing et al., 
2018; Yan et al., 2014). Overexpression of 
PRMT5 promotes proliferation, while inhibi-
tion of PRMT5 impedes cell growth (Kark-
hanis et al., 2011; Yang and Bedford, 2013).  
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Figure 4: PRMT5 inhibition induces NF-кB inactivation in bladder cancer. A. shPRMT5 reduced 
NF-κB activation in T24 cells. B. EPZ015666 decreased NF-κB activation in a dose-dependent manner. 
C. shPRMT5 reduced NF-κB target genes (BCLXL and c-IAP1) expression. D. EPZ015666 decreased 
BCLXL and c-IAP1 expression. *P < 0.05 vs. control group. E. EPZ015666 (200 µM) impairs NF-κB 
enrichment on the BCLXL and c-IAP1 promoters. ChIP was performed using IgG or NF-κB p65 antibody; 
*, P < 0.05; **, P < 0.01 vs. control. 
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Figure 5: Pharmacological inhibition of PRMT5 has strong anti-tumor effects. T24 cells were in-
jected into mice. EPZ015666 were administrated 14 days after injection. A. Morphology of subcutaneous 
tumors at 4 weeks after transplantation. B. Body weight of mice dosed with oral EPZ or vehicle (Control). 
C. Tumor volume over time as indicated. D. Tumor weight at 4 weeks after transplantation. E. qRT-PCR 
analysis of mRNA level of BCLXL and c-IAP1 in excised tumors. *P < 0.05, ** P < 0.01 vs. control. 
 
 
 
The recent report indicated that PRMT5 
overexpressing causes tumor suppressor p53 
function loss, further implying PRMT5’s crit-
ical role as an oncoprotein (Li et al., 2015). 
Nevertheless, the role of PRMT5 in bladder 
cancer, to our knowledge, is never reported. 
Notably, in the current study, overexpression 
of PRMT5 was observed in both human blad-
der cancer cell lines and patients. Our findings 
that PRMT5 inhibition induced cell apoptosis 
and growth suppression further confirmed 
that PRMT5 contributes directly to manifes-
tation of the malignancy in human bladder 
cancer. 
The NF-κB transcription family plays 
substantial roles in tumorigenesis as well as in 
the immune and inflammatory system. NF-κB 
signaling pathway consists of the most com-
mon heterotrimer of p50 and p65, which bind 
to its inhibitory protein IκBα. IκBα is the in-
active form, masking the nuclear localiza-
tion signal (Karin, 2006; Lu and Stark, 2015). 
Posttranscriptional modification of IκBα such 
as phosphorylation, ubiquitination, and deg-
radation results in the release of the p50-p65 
subunits from IκB and their nuclear transloca-
tion, generally causing transcription activa-
tion of multiple target genes (Lu and Stark, 
2015). It’s reported that PRMT5 binds to the 
TRAIL receptor and thus contributed to 
TRAIL-induced NF-κB activation by Tanaka 
et al. (2009). Multiple groups have proved 
that symmetrical dimethylation of NF-κB p65 
by PRMT5 reinforces NF-κB transactivation 
activity (Harris et al., 2014, 2016; Wei et al., 
2013). We found here that PRMT5 can reduce 
bladder cancer cell apoptosis by upregulating 
NF-κB activity, thereby potentiating cellular 
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proliferation. We further confirmed the tu-
morigenic function of the PRMT5/NF-κB 
axis in vivo using xenograft tumor models. 
Our results demonstrate the carcinogenic 
function of the PRMT5/NF-κB signaling in 
bladder cancer and the role of PRMT5 inhib-
itor as a potent agent for the strategic therapy 
for bladder cancer. 
It’s well established that NF-κB activation 
plays central roles in the regulation of apop-
tosis (Van Antwerp et al., 1996). The anti-
apoptotic target genes of NF-κB trigger the 
immune and genomic surveillance system to 
exclude the malignant and pre-malignant 
cells. These anti-apoptotic genes include Bcl-
2, FLIP and XIAP (inhibitors of apoptosis) 
families (Fan et al., 2008). NF-κB diminishes 
TNF-induced JNK activation and apoptosis 
by intensifying XIAP and GADD45β expres-
sion (De Smaele et al., 2001). Our in vitro and 
in vivo results showed that PRMT5 inhibition 
is a major driver for activation of NF-kB-de-
pendent anti-apoptotic genes c-IAP1 and 
BCLXL by NF-kB enrichment on the target 
promoter, providing mechanistic insights into 
its contribution to tumorigenesis and its influ-
ential to determine its potent as a therapeutic 
target. 
In conclusion, our work illustrated that 
PRMT5 is highly expressed in bladder cancer 
cell lines and patients. Importantly, PRMT5 
inhibition significantly represses bladder can-
cer cell proliferation and invasive bladder 
cancer growth by activation of critical NF-кB 
dependent anti-apoptotic genes. These find-
ings indicated that PRMT5 may be an essen-
tial biomarker or drug target of bladder can-
cer. 
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